On the management of metastatic prostate cancer with LH-RH analogs.

Abstract

With the availability of luteinizing hormone releasing hormone (LH-RH) agonists, and in the future of maybe also of LH-RH antagonists, new principles were introduced into the clinical management of human prostate carcinoma and other steroid-hormone-dependent tumors (Schröder et al. 1987). LH-RH agonists offered a new principle of suppressing testicular androgen to castration levels, the major advantage of which over the classical forms of treatment with estrogen administration or castration seemed to be an absence of physical side effects and a reduction of physiological side effects. For these advantages a much higher price has to be paid, and it now remains questionable in how far LH-RH agonists will be able to compete with other principles of castration in the management of this disease.KeywordsAdvanced Prostate CancerMetastatic Prostate CancerPlasma TestosteroneLuteinizing Hormone Release HormoneLHRH AgonistThese keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.